DeepMed Research

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Cell culture derived seasonal trivalent influenza vaccine (cTIV)
Biological: cTIV+PV OR eTIV_a+PV
Biological: Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
Biological: cTIV or eTIV_a

First Posted Date: 2007-12-24

Last Posted Date: 2017-01-27

Lead Sponsor: Novartis

Target Recruit Count: 1522

Registration Number: NCT00579345

Locations: 🇵🇱
4, Krakow, Poland
🇵🇱
1, Krakow, Poland
🇵🇱
3, Krakow, Poland

and more 2 locations

Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel in Patients With Acute Ankle Sprain

Phase 2

Completed

Conditions: Ankle Sprain

Interventions: Drug: Diclofenac diethylamine 2.32% gel
Drug: Placebo
Drug: Diclofenac diethylamine 2.32% gel / Placebo

First Posted Date: 2007-12-14

Last Posted Date: 2012-04-20

Lead Sponsor: Novartis

Target Recruit Count: 271

Registration Number: NCT00573768

Locations: 🇩🇪
Novartis Investigative Site, Stockach, Germany

Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: vildagliptin

First Posted Date: 2007-12-13

Last Posted Date: 2012-05-02

Lead Sponsor: Novartis

Target Recruit Count: 29

Registration Number: NCT00572650

Locations: 🇩🇪
Novartis Investigator Site, Kiel, Germany

Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.

Phase 1

Completed

Conditions: COPD

Interventions: Drug: QAX028
Drug: Placebo
Drug: Tiotropium bromide

First Posted Date: 2007-12-06

Last Posted Date: 2011-04-28

Lead Sponsor: Novartis

Target Recruit Count: 29

Registration Number: NCT00568503

Locations: 🇩🇰
Novartis Investigator Site, Birkeroed, Denmark

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

Phase 1

Completed

Conditions: Coronary Heart Disease

Interventions: Drug: APL180
Drug: Placebo

First Posted Date: 2007-12-06

Last Posted Date: 2020-12-24

Lead Sponsor: Novartis

Target Recruit Count: 176

Registration Number: NCT00568594

Locations: 🇬🇧
Novartis Investigator Site, Harrow, United Kingdom

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Indacaterol 150 μg
Drug: Salmeterol 50 μg
Drug: Placebo to Indacaterol
Drug: Placebo to Salmeterol

First Posted Date: 2007-12-05

Last Posted Date: 2011-08-18

Lead Sponsor: Novartis

Target Recruit Count: 1002

Registration Number: NCT00567996

Locations: 🇫🇷
Novartis Investgative Site, Ferolles-Attilly, France
🇮🇹
Novartis investigator site, Chieti, Italy
🇮🇹
Novartis Investigative Site, Ascoli Piceno, Italy

and more 3 locations

Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Omalizumab
Drug: Inhaled corticosteroids (ICS)
Drug: Long-acting beta 2-adrenergic agonist (LABA)
Drug: Short-acting beta 2-adrenergic agonist (SABA)

First Posted Date: 2007-12-05

Last Posted Date: 2011-06-30

Lead Sponsor: Novartis

Target Recruit Count: 116

Registration Number: NCT00567476

Locations: 🇧🇷
Novartis Investigator Site, São Paulo, Brazil

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Phase 1

Completed

Conditions: Type-2 Diabetes

Interventions: Drug: vildagliptin

First Posted Date: 2007-12-04

Last Posted Date: 2009-03-25

Lead Sponsor: Novartis

Target Recruit Count: 96

Registration Number: NCT00567047

Locations: 🇩🇪
Novartis Investigator Site, Kiel, Germany

Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rivastigmine 5 and 10 cm^2 patch

First Posted Date: 2007-11-21

Last Posted Date: 2012-04-16

Lead Sponsor: Novartis

Target Recruit Count: 208

Registration Number: NCT00561392

Locations: 🇩🇪
Novartis Investigative Site, Munich, Germany

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Phase 1

Completed

Conditions: Influenza Infection

Interventions: Biological: Adjuvanted influenza vaccine combined with CpG7909
Biological: Adjuvanted influenza vaccine combine with CpG7909
Biological: Subunit influenza vaccine
Biological: Adjuvanted influenza vaccine

First Posted Date: 2007-11-19

Last Posted Date: 2009-11-05

Lead Sponsor: Novartis

Target Recruit Count: 60

Registration Number: NCT00559975

Locations: 🇨🇭
Institute for Pharmacokinetic and Analytical Studies, Ligornetto, Switzerland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy